Renaissance Technologies
ENGN icon

Renaissance Technologies’s enGene Therapeutics ENGN Stock Holding History

Renaissance Technologies’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.44M Buy
829,700
+673,600
+432% +$2.75M ﹤0.01% 2146
2026
Q1 		$1.06M Buy
156,100
+135,318
+651% +$1.2M ﹤0.01% 2239
2025
Q4 		$188K Buy
+20,782
New +$167K ﹤0.01% 2901
2025
Q3 		– Sell
-11,400
Closed -$41.5K – 3599
2025
Q2 		$41.5K Buy
+11,400
New +$42.8K ﹤0.01% 3417

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Renaissance Technologies's ENGN Position: Q2 2026 in Review

Renaissance Technologies increased its enGene Therapeutics (ENGN) stake by 432% in Q2 2026, buying an estimated $2.75M and bringing the position to 829,700 shares worth $1.44M. The position accounts for ﹤0.01% of the portfolio, ranked #2146.

Renaissance Technologies first reported a position in ENGN in Q2 2025 and has held it in 4 quarters since. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Renaissance Technologies held 829,700 shares of enGene Therapeutics worth $1.44M as of Q2 2026.
  • Renaissance Technologies bought 673,600 enGene Therapeutics shares in Q2 2026, an estimated $2.75M.
  • enGene Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2146 holding.
  • Renaissance Technologies first reported a position in enGene Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.